These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
277 related articles for article (PubMed ID: 9987189)
1. Comparative in-vitro activities of trovafloxacin, ciproflaxacin, ofloxacin, and broad-spectrum beta-lactams against aerobe blood culture isolates. Seifert H Zentralbl Bakteriol; 1998 Dec; 288(4):509-18. PubMed ID: 9987189 [TBL] [Abstract][Full Text] [Related]
2. Antibacterial activity of trovafloxacin against nosocomial Gram-positive and Gram-negative isolates. Cunha BA; Qadri SM; Ueno Y; Walters EA; Domenico P J Antimicrob Chemother; 1997 Jun; 39 Suppl B():29-34. PubMed ID: 9222067 [TBL] [Abstract][Full Text] [Related]
3. Comparison of in vitro activity of trovafloxacin against gram-positive and gram-negative organisms with quinolones and beta-lactam antimicrobial agents. Dembry LM; Roberts JC; Schock KD; Marino SP; Farrel PA; Andriole VT Diagn Microbiol Infect Dis; 1998 May; 31(1):301-11. PubMed ID: 9597391 [TBL] [Abstract][Full Text] [Related]
4. Comparative in vitro activity of gemifloxacin, ciprofloxacin, levofloxacin and ofloxacin in a North American surveillance study. Hoban DJ; Bouchillon SK; Johnson JL; Zhanel GG; Butler DL; Miller LA; Poupard JA; Diagn Microbiol Infect Dis; 2001; 40(1-2):51-7. PubMed ID: 11448564 [TBL] [Abstract][Full Text] [Related]
6. In vitro activity of trovafloxacin (CP 99,219), a new fluoroquinolone against hospital isolates. Ling TK; Liu EY; Cheng AF Chemotherapy; 1999; 45(1):22-7. PubMed ID: 9876206 [TBL] [Abstract][Full Text] [Related]
7. In-vitro activity of trovafloxacin against clinical bacterial isolates from patients with cancer. Rolston KV; Ho DH; LeBlanc B; Streeter H; Dvorak T J Antimicrob Chemother; 1997 Jun; 39 Suppl B():15-22. PubMed ID: 9222065 [TBL] [Abstract][Full Text] [Related]
8. Comparative activity of trovafloxacin, alone and in combination with other agents, against gram-negative nonfermentative rods. Visalli MA; Bajaksouzian S; Jacobs MR; Appelbaum PC Antimicrob Agents Chemother; 1997 Jul; 41(7):1475-81. PubMed ID: 9210669 [TBL] [Abstract][Full Text] [Related]
9. In-vitro activities of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, pefloxacin, sparfloxacin and trovafloxacin against gram-positive and gram-negative pathogens from respiratory tract infections. Hoogkamp-Korstanje JA J Antimicrob Chemother; 1997 Sep; 40(3):427-31. PubMed ID: 9338498 [TBL] [Abstract][Full Text] [Related]
10. In-vitro activity of trovafloxacin against sensitive and resistant aerobic bacteria using the standard microdilution broth method and Etest. Dembry LM; Farrel PA; Orcutt DR; Gerrity LA; Andriole VT J Antimicrob Chemother; 1997 Jun; 39 Suppl B():35-42. PubMed ID: 9222068 [TBL] [Abstract][Full Text] [Related]
11. Comparative in vitro activities of trovafloxacin (CP-99,219) against 445 gram-positive isolates from patients with endocarditis and those with other bloodstream infections. Endtz HP; Mouton JW; den Hollander JG; van den Braak N; Verbrugh HA Antimicrob Agents Chemother; 1997 May; 41(5):1146-9. PubMed ID: 9145886 [TBL] [Abstract][Full Text] [Related]
12. The in-vitro activity of trovafloxacin, a new fluoroquinolone, against Gram-positive bacteria. Sefton AM; Maskell JP; Rafay AM; Whiley A; Williams JD J Antimicrob Chemother; 1997 Jun; 39 Suppl B():57-62. PubMed ID: 9222071 [TBL] [Abstract][Full Text] [Related]
13. In vitro antibacterial activity of trovafloxacin and five other fluoroquinolones. Montanari MP; Prenna M; Mingoia M; Ripa S; Varaldo PE Chemotherapy; 1998; 44(2):85-93. PubMed ID: 9551237 [TBL] [Abstract][Full Text] [Related]
14. Comparative antimicrobial susceptibility of aerobic and facultative bacteria from community-acquired bacteremia to ertapenem in Taiwan. Lee SC; Huang SS; Lee CW; Fung CP; Lee N; Shieh WB; Siu LK BMC Infect Dis; 2007 Jul; 7():79. PubMed ID: 17640342 [TBL] [Abstract][Full Text] [Related]
15. Comparative in vitro activity of gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin and trovafloxacin against 4151 Gram-negative and Gram-positive organisms. Blondeau JM; Laskowski R; Bjarnason J; Stewart C Int J Antimicrob Agents; 2000 Feb; 14(1):45-50. PubMed ID: 10717500 [TBL] [Abstract][Full Text] [Related]
16. In vitro antibacterial activity of moxifloxacin against hospital isolates: a multicentre study. Soussy CJ; Nguyen J; Goldstein F; Dabernat H; Andremont A; Leclercq R; Drugeon H; Cavallo P; Chardon H; Etienne J; Rio Y; Courvalin P Clin Microbiol Infect; 2003 Oct; 9(10):997-1005. PubMed ID: 14616741 [TBL] [Abstract][Full Text] [Related]
17. Bacteriological activity of trovafloxacin, a new quinolone, against respiratory tract pathogens. Pechère JC; Gootz TD Eur J Clin Microbiol Infect Dis; 1998 Jun; 17(6):405-12. PubMed ID: 9758283 [TBL] [Abstract][Full Text] [Related]
18. Comparative in vitro potency of gemifloxacin and fluoroquinolones against recent European clinical isolates from a global surveillance study. Hoban DJ; Bouchillon SK; Johnson JL; Zhanel GG; Butler DL; Miller LA; Poupard JA; Eur J Clin Microbiol Infect Dis; 2001 Nov; 20(11):814-9. PubMed ID: 11783700 [TBL] [Abstract][Full Text] [Related]
19. Trovafloxacin susceptibility of aerobic clinical bacterial isolates from Sweden. Rylander M; Walder M; Lind-Brandberg L; Larsson P; Törnqvist E; Monsen T; Kronvall G Scand J Infect Dis; 1999; 31(6):567-72. PubMed ID: 10680987 [TBL] [Abstract][Full Text] [Related]
20. In vitro activity of gemifloxacin against a broad range of recent clinical isolates from the USA. McCloskey L; Moore T; Niconovich N; Donald B; Broskey J; Jakielaszek C; Rittenhouse S; Coleman K J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():13-21. PubMed ID: 10824027 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]